Exposure-response methods and dose approval of new oncology drugs by FDA from 2005 to 2015.

被引：4
|
作者：
Minchella, Kaitlyn [1 ]
Xu, Hongmei [1 ]
Al-Huniti, Nidal [1 ]
机构：
[1] AstraZeneca, Waltham, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.2530
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2530
引用
收藏
页数：2
相关论文
共 36 条
  • [31] Population pharmacokinetic and exposure-response analyses from ALTA-1L: Model-based analyses supporting the brigatinib dose in ALK-positive NSCLC
    Gupta, Neeraj
    Reckamp, Karen L.
    Camidge, David R.
    Kleijn, Huub J.
    Ouerdani, Aziz
    Bellanti, Francesco
    Maringwa, John
    Hanley, Michael J.
    Wang, Shining
    Zhang, Pingkuan
    Venkatakrishnan, Karthik
    [J]. CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2022, 15 (05): : 1143 - 1154
  • [32] Population Pharmacokinetics and Exposure-Response Analyses from Phase I-III Studies Support Copanlisib Dose Selection in Relapsed Indolent Non-Hodgkin Lymphoma
    Moss, Jonathan
    Garmann, Dirk
    Austin, Rupert
    Hiemeyer, Florian
    Matasar, Matthew J.
    Zinzani, Pier Luigi
    Beckert, Vita
    Soler, Lidia Mongay
    Childs, Barrett H.
    Morcos, Peter N.
    [J]. BLOOD, 2022, 140 : 3629 - 3631
  • [33] EXPOSURE-RESPONSE MODELING OF DIZZINESS, THE DOSE-LIMITING ADVERSE EVENTS IN A FTIH STUDY OF A NEW GLYCINE TRANSPORTER1 INHIBITOR USING A MARKOV MIXED-EFFECTS MODEL
    Wang, T.
    Murthy, V.
    Ouellet, D.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 : S82 - S82
  • [34] Predicting Clinical Dose-Exposure and Exposure-Response Relationships of Pan-Antiapoptotic BCL-2 Family Inhibitor Obatoclax in MLL Rearranged Infant Leukemias From Preclinical Disease Models and Adult Experience
    Barrett, Jeffrey S.
    Zhang, Alena Y.
    Urtishak, Karen A.
    Danet-Desnoyers, Gwenn
    Carroll, Andrew J.
    Hunger, Stephen P.
    Felix, Carolyn A.
    [J]. BLOOD, 2011, 118 (21) : 1107 - 1108
  • [35] Herausforderungen komplexer Studiendesigns bei der Zulassung von neuen Onkologika aus Sicht des BfArMChallenges to approval of new oncology drugs by complex study designs from the perspective of the BfArM
    Martin Mengel
    Claudia Riedel
    Ulrike Hermes
    [J]. Forum, 2021, 36 (6) : 497 - 500
  • [36] Dose- and exposure-response relationship and biomarker correlation analysis in breast tumors from patients treated with capivasertib, an AKT inhibitor, in the STAKT randomized, placebo controlled pre-surgical study
    Gee, J.
    Coleman, R. E.
    Cheung, K. L.
    Evans, A.
    Holcombe, C.
    Skene, A.
    Rea, D.
    Ahmed, S.
    Jahan, A.
    Horgan, K.
    Rauchhaus, P.
    Littleford, R.
    Finlay, P.
    Cheung, A.
    Cullberg, M.
    de Bruin, E.
    Foxley, A.
    Koulai, L.
    Pass, M.
    Schiavon, G.
    Rugman, P.
    Deb, R.
    Robertson, J. F. R.
    [J]. CANCER RESEARCH, 2019, 79 (04)
1234